First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Abstract | BACKGROUND: PATIENTS AND METHODS: Patients with HER2-negative LR/mBC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two and no prior chemotherapy for LR/mBC received bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks plus taxane-based chemotherapy (or other non- anthracycline chemotherapy) until disease progression, unacceptable toxicity or patient withdrawal. The primary end point was safety; time to progression ( TtP) was a secondary end point. RESULTS: CONCLUSIONS: The study population in ATHENA was more representative of general oncology practice than populations enrolled into randomised trials, although there may have been some bias towards younger, fitter patients. The safety and efficacy of bevacizumab- taxane therapy in this large study were consistent with results from randomised first-line trials.
|
Authors | I E Smith, J-Y Pierga, L Biganzoli, H Cortés-Funes, C Thomssen, X Pivot, A Fabi, B Xu, D Stroyakovskiy, F A Franke, B Kaufman, P Mainwaring, T Pienkowski, B De Valk, A Kwong, J L González-Trujillo, I Koza, K Petrakova, D Pereira, K I Pritchard, ATHENA Study Group |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 22
Issue 3
Pg. 595-602
(Mar 2011)
ISSN: 1569-8041 [Electronic] England |
PMID | 20819780
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Bridged-Ring Compounds
- Receptors, Estrogen
- Receptors, Progesterone
- Taxoids
- taxane
- Bevacizumab
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bevacizumab
- Bone Neoplasms
(drug therapy, secondary)
- Brain Neoplasms
(drug therapy, secondary)
- Breast Neoplasms
(drug therapy, pathology, surgery)
- Bridged-Ring Compounds
(administration & dosage)
- Drug-Related Side Effects and Adverse Reactions
- Female
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms
(drug therapy, secondary)
- Lung Neoplasms
(drug therapy, secondary)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Receptor, ErbB-2
(metabolism)
- Receptors, Estrogen
(metabolism)
- Receptors, Progesterone
(metabolism)
- Taxoids
(administration & dosage)
- Treatment Outcome
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|